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Colorectal carcinoma is a significant cause of morbidity and
mortality world-wide. In the UK, it is the second most common
cause of cancer death, accounting for 19 000 deaths per year
(Cancer Research Campaign Factsheets, 1993). Although under-
standing of the molecular basis of colorectal carcinoma is rapidly
increasing (Groden et al, 1991; Leache et al, 1993), many addi-
tional factors remain to be elucidated. It is clear that genetic
factors are important in colorectal tumorigenesis (Cannon-
Albright et al, 1988; Vogelstein et al, 1988) but it is likely that
hormones and locally acting growth factors are also important in
the development and progression of the disease. Breast cancer is a
paradigm in this respect, exhibiting both genetic alterations and
sensitivity to endocrine factors, which has been exploited thera-
peutically with the use of oestrogen receptor antagonists (Santen et
al, 1990). The gastrointestinal tract is a rich source of peptide
hormones. Functional conservation of peptide hormone receptors
following malignant transformation in the colon may permit
susceptibility to the therapeutic manipulation of the actions of
endogenous trophic hormones.
Bombesin, an amphibian tetradecapeptide, exerts a wide range
of effects on the mammalian gastrointestinal tract and bombesin-
like immunoreactivity has been demonstrated in the submucosal
and myenteric plexuses throughout the gut. The search for
mammalian bombesin-like peptides resulted in the discovery of
gastrin releasing peptide (GRP) (McDonald et al, 1979) and
neuromedin B (NMB) (Minamino et al, 1983). These bombesin-
like peptides regulate gut motility, influence secretion of enteric
peptide hormones and pancreatic exocrine secretion (reviewed in
Sunday et al, 1988). The genes encoding GRP and NMB have
been cloned and sequenced. A single GRP-encoding gene has been
localized to chromosome 18 (Spindel et al, 1984; Naylor et al,
1987). Alternate splicing produces three different transcribed GRP
mRNAs which are translated into GRP preprohormones each
differing in their C-terminal extension peptide (Sausville et al,
1986; Spindel et al, 1986). Similarly, molecular cloning from
human hypothalamus has identified a single NMB gene on chro-
mosome 15, two transcribed mRNAs and a 76 amino acid NMB
preprohormone (Krane et al, 1988). The mechanism responsible
for the production of two NMB mRNAs has yet to be determined.
The natural ligand for BRS-3 has not been identified, but studies
with a synthetic antagonist have demonstrated high affinity
binding to the BRS-3 receptor (Mantey et al, 1997).
To date three bombesin-like peptide receptors have been
isolated and cloned. The GRP receptor is found in the gut, from
oesophagus to rectum (Sunday et al, 1988; reviewed in Spindel
et al, 1993); the NMB receptor is present in the oesophageal
muscularis mucosa (von Schrenck et al, 1989) and smooth muscle
cells from the rectosigmoid colon (Bitar et al, 1993); and expres-
sion of the bombesin receptor subtype 3 (BRS-3) is limited, in rats,
to germ cells in the testes but is present in a range of human lung
cancer cells (Corjay et al, 1991; Fathi et al, 1993). The human
GRP receptor and NMB receptor were cloned from placental and
peripheral blood genomic libraries, and human small-cell lung
cancer (SCLC) cell lines (Corjay et al, 1991). The GRP receptor
gene was localized to the X chromosome on the human genome
between p11 and q11 (Schantz et al, 1991) and the NMB receptor
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1991). Later, the BRS-3 gene was mapped on human chromosome
X (Fathi et al, 1993).
Bombesin-like peptides are mitogenic for Swiss 3T3 fibroblasts
(Rozengurt et al, 1983) and human SCLC cell lines (Weber et al,
1985). In vivo and in vitro studies have demonstrated mitogenic
effects on a number of gastrointestinal mucosal and cancer cells
(Preston et al, 1996). In SCLC and human pancreatic cancer cells
an autocrine loop has been demonstrated (Cuttita et al, 1985; Wang
et al, 1996).
We have previously shown, by means of radioligand binding
studies, that GRP receptors are expressed in 24% of colorectal
cancers (Preston et al, 1995), which is in agreement with previous
reports (Radulovic et al, 1992). These binding sites are not
detected in normal colonic mucosa. High-affinity functional GRP
binding sites are present on the human cancer cell line
Colo320HSR (Hirai et al, 1993; Preston et al, 1994). Inhibition of
the growth of Colo320HSR by a GRP antagonist has also been
demonstrated in vivo using a clonogenic assay (Preston at al,
1994). In this cell line at least, GRP may act as an autocrine growth
factor.
The possibility that GRP is an autocrine growth factor in
colorectal cancer warrants further investigation using more
powerful methodologies. In the absence of validated antibodies for
the GRP receptor, we have used the molecular techniques of
reverse transcription polymerase chain reaction (RT-PCR) and in
situ hybridization (ISH) to detect and then localize steady-state
levels of mRNA for the bombesin-like peptides and their receptors
in human colorectal cancers and matched normal mucosa.
MATERIALS AND METHODS
Twenty-three specimens of colorectal cancer tissue and paired
normal mucosal samples, four polyps and two colorectal liver
metastases were studied (Table 1).
Tissue collection
All samples were obtained fresh, snap-frozen in liquid nitrogen
and stored at –80°C.
RNA extraction
Total cellular RNA was extracted from frozen tissue using the
RNeasy kit (Qiagen, Dorking, Surrey, UK).
Reverse transcription
Reverse transcription was performed by 400 U MMLV-RT
(Gibco-BRL, Paisley, Scotland) in 1X manufacturers buffer
containing 0.5 mM dNTPs, 10 mM dithiothreitol (DTT) and 0.05
units pdT(12–18) primer (Pharmacia, St Albans, Herts, UK).
cDNA integrity was verified by PCR amplification of a fragment
of the constitutively expressed b-actin gene (primers and condi-
tions obtained from Stratagene).
Polymerase chain reaction
Primers, determined from published cDNA sequences (Spindel et
al, 1984; Krane et al, 1988; Corjay et al, 1991; Fathi et al, 1993)
(Table 2), were designed to span an intron hence avoiding confu-
sion between RNA and genomic DNA-derived products. Thermal
cycling, with appropriate positive and negative controls, was
performed at 0.25 mM final concentration using 250 mM of each
dNTP, 1.25 U Taq polymerase (Amersham, Little Chalfont, Bucks,
UK) in manufacturers buffer containing 2 mM magnesium chloride
(MgCl2) and 2% dimethyl sulphoxide (DMSO) (Sigma, Poole,
Dorset, UK) for GRP receptor; 2.5 mM MgCl2 without DMSO for
GRP ligand; 3 mM MgCl2 and 1% DMSO for NMB receptor;
1.5 mM MgCl2 and 2% DMSO for NMB ligand and BRS-3
receptor. Cycling was carried out on a Techne PHC3 thermal
cycler with an initial denaturing step of 3 min at 94°C, followed by
30 cycles of 94°C denaturation for 30 s, annealing at 62°C (GRP-
R); 56°C (GRP-L); 56°C (NMB-R); 66°C (NMB-L); 56°C (BRS-
3-R) for 30 s and 72°C polymerization for 30 s. This was followed
by a final extension step of 72°C for 2 min to ensure completion of
all initiated polymerization events.
Products were resolved on 8% non-denaturing polyacrylamide
gel, stained with ethidium bromide, visualized by UV transillumi-
nation and photographed.
The results of the RT-PCR were semi-quantified by scoring the
intensity of the receptor or ligand band compared with the inten-
sity of the b-actin band using the same amount of starting
template. By this means we were able to directly compare scores
between tumour and mucosa and make a semi-quantatative assess-
ment of their relative abundance. This assessment used a 5 point
arbitrary scale; 0 – no expression compared to b-actin; 1–very
weak expression; 2 – weak expression; 3 – strong expression; 4 –
expression equal to, or greater than, b-actin. For each specimen the
PCR was repeated 3 times and the scores added. Thus, a total score
range of 0–12 could be obtained. The scoring was performed by an
observer unaware of the nature of the products being evaluated.
Confirmation of the nature of the PCR product was accom-
plished by restriction enzyme digestion and cloning (data not
shown). PCR products were cloned into PGEM®-Teasy (Promega),
transformed into competent Escherichia coli cells and character-
ized by dideoxy sequencing using the T7 kit obtained from
Pharmacia Biotech. For each receptor and ligand subtype cloned,
the anticipated PCR product was obtained.
In situ hybridization
In situ hybridization was performed on a subset of matched
tumour–mucosa pairs using a 188 bp digoxigenin labelled ribo-
probe for GRP-receptor, and 310 bp digoxin-labelled riboprobe for
GRP-ligand. Ten micron cryostat sections of frozen tumour were
taken and fixed for 4 min in 4% paraformaldehyde at 4°C. After
washing twice for 10 min in DEPC-treated water, sections were
prehybridized in 40% deionized formamide, 5 ´ SSPE, 1 ´
Denhardt’s solution, 0.05 M DTT and 1.5 units ml–1 sonicated
salmon sperm for 1 h at 48°C for GRP-R and 38°C for GRP-L.
Hybridization was carried out overnight at the same temperature
with 500 mg ml–1 of riboprobe in prehybridisation solution with
10% dextran sulphate.
Non-hybridized probe was removed by washing with 2 ´ SSC
(standard saline citrate) for 5 min, 1 ´ SSC for 5 min and 0.2 ´
SSC for 10 min. Sections were incubated in blocking solution (3%
bovine serum albumin (BSA) in 25 mM Tris-buttered saline (TBS)
with 0.1% Triton X) for 30 min at room temperature. Anti-
digoxigenin antibody (Boehringer Mannheim, Lewes, Sussex,
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90 min. Unbound antibody was washed off with diluted blocking
solution (0.1% in TBS) twice for 5 min. This was followed by
incubation with 1/30 dilution of blocking solution twice for 5 min.
Hybridized probe was visualized by anti-digoxigenin antibody
conjugated to an alkaline phosphatase detection system
(Boehringer Mannheim Biochemica). For each sample, a control
reaction was carried out on an adjacent tissue section using a sense





The pathological details are summarized in Table 1. Tumour, with
a sample of normal tissue taken from as far away as possible from
the tumour, but not involving the resection margins, was obtained
from 14 male and 11 female patients with a median age of 74 years
(range 52–86 years).
Cancer
The nature of all tissues was verified by a consultant histopatholo-
gist. All cancers were adenocarcinomas. Three carcinomas were
from the ascending colon, three transverse colon, three descending
colon, three sigmoid colon and 11 from the rectum. Dukes’ stage
‘D’ has been included to represent all samples of primary tumour
where distant metastases were present at the time of the initial
resection. Staging of tumours were as follows; 4% Dukes’ A, 52%
Dukes’ B, 31% Dukes’ C and 13% Dukes’ D. Of tumours, 13%
were well differentiated, 65% moderately differentiated and 22%
poorly differentiated (Table 1).
The four polyps were all rectal in origin and two were from
patients who also had cancers resected. Three were dysplastic
villous adenomas and the remaining one a tubular adenoma.
Two liver metastases were taken from patients who had rectal
tumours.
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Table 1 Summary of clinical, pathological and experimental data for the analysis of bombesin-like receptors and ligand mRNA expression in colorectal cancer
Patient Grade Dukes’ stage Site *GRP
number (differentiation) receptor *GRP *NMB
mRNA mRNA mRNA
expression expression expression
TN T N TN
1 Moderately A Rectum 9 5 9 6 8 7
2 Well B Ascending 3 1 12 4 8 6
3 Moderately B Rectum 3 4 7 3 1 5
4 Moderately B Rectum 9 7 7 5 12 3
5 Moderately B Transverse 6 8 9 11 7 1
6 Poor B Ascending 11 5 4 3 12 11
7 Moderately C Ascending 10 9 10 8 8 5
8 Moderately C Descending 6 4 7 5 11 5
9 Severely TVA polyp Sigmoid 6 5 7 6 8 7
dysplastic
10 Moderately B Rectum 8 5 8 8 4 2
TVA polyp Rectum 5 5 1
11 Moderately B Descending 10 9 10 6 7 7
12 Moderately C Rectum 8 6 11 9 6 4
13 Moderately C Rectum 8 9 11 11 11 10
14 Poor D Rectum 11 9 8 6 7 5
Liver met 8 3 6
15 Well B Transverse 10 4 12 8 11 12
16 Severely TVA polyp Rectum 7 5 7 12 12 4
dysplastic
17 Poor B Sigmoid 9 4 4 4 4 5
18 Poor D Rectum 9 7 4 10 9 5
Liver met 5 8 5
19 Mod B Transverse 9 8 10 8 11 2
20 Mod B Rectum 5 3 11 9 12 0
TA polyp Rectum 2 10 5
21 Mod B Sigmoid 6 6 4 6 7 6
22 Mod C Rectum 9 9 8 6 7 2
23 Poor C Rectum 4 8 10 7 12 11
24 Poor C Descending 5 8 6 4 6 7
25 Well D Sigmoid 10 9 6 8 2 8
T>N 18 17 19
T=N 2 3 1
T<N 5 5 5
T = tumour; N = normal mucosa; TA = tubular adenoma; TVA = tubulovillous adenoma. *Scored as sum of 3 determinations with score 0–4 (i.e. 0–12) when
compared to b-actin expression, where 0, no expression; 1, very weak expression; 2, weak expression; 3, strong exprssion; and 4, equally or greater expressed
than b-actin.Receptors
All specimens expressed detectable levels of mRNA for the GRP
receptor (Table 1). In 16 of the 23 matched cancer–mucosa pairs
there was overexpression of GRP receptor mRNA in tumour
compared to the mucosa (Figure 1). Two of four polyps studied
also demonstrated relative overexpression of GRP receptor
mRNA. Relative overexpression in the tumours appeared to be
more prevalent in the earlier staged tumours but numbers
precluded statistical evaluation. There was no correlation between
GRP mRNA expression and degree of differentiation or site of
tumour. Both metastases demonstrated lower expression than that
of the matched tumour. NMB and BRS-3 receptor mRNA was not
detected in any samples.
Ligands
GRP mRNA and the alternate donor site mRNA were identified
using primers that flank a potential site for alternate splicing. The
products were verified by cloning and sequencing. Both GRP and
the alternate donor site mRNA were expressed at detectable levels
in all tumour and mucosal samples (Table 1). Comparing tumour
to normal mucosa there was apparent overexpression in 16 of the
23 cancer–mucosa pairs. Although there was some variation in the
expression of GRP ligand and its spliced variant there was no
consistent pattern. One of the four polyps demonstrated greater
expression than matched mucosa. One metastasis demonstrated
greater expression and the other lower expression than matched
tumour.
The NMB-ligand mRNA was expressed in all but one mucosal
samples, and in all tumour samples. It was clearly overexpressed
in tumour in 17 of the 23 cancer–mucosa pairs (Table 1). Three of
the four polyps showed greater expression than matched mucosa.
Both metastases showed lower expression than the tumour.
Thirteen of the 23 cancer–mucosa pairs showed tumour over-
expression of mRNA for GRP receptor, and GRP and NMB ligand.
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Figure 1 RT-PCR analysis of GRP receptor mRNA expression in colorectal
cancers and matched normal mucosa (all had comparable levels of b-actin
mRNA expression)
Figure 2 Frozen sections of normal colonic mucosa following in situ
hybridization with antisense (A) and sense (B) riboprobes specific for GRP
receptor (patient 12, Table 1)
Figure 3 Frozen sections of normal mucosa following in situ hybridization




BIn situ hybridization was used to localize cells expressing
mRNA for both the GRP receptor and ligand. All tumour and
mucosal samples expressed mRNA for both the receptor and
ligand. Expression was localized to the epithelial cells. GRP
receptor mRNA expression appeared most prominant at the baso-
lateral aspect of the mucosal cells (Figure 2), whereas GRP ligand
mRNA expression appeared to be maximal at the luminal surface
(Figure 3). In the tumour samples, although clearly positive for
both the receptor and ligand mRNA, no particular pattern of
expression could be determined (Figure 4).
DISCUSSION
In this study we have determined the receptor and ligand expres-
sion of the known mammalian bombesin-family peptides in
benign and malignant human colon tissue by RT-PCR and ISH.
The lack of reliably specific monoclonal antibodies and the rela-
tive insensitivity of autoradiography currently renders detection of
the gene product problematic. We therefore elected to analyse the
steady-state levels of messenger RNA for each receptor and
ligand. RT-PCR was chosen because it is an exquisitely sensitive
technique that will amplify small quantities of messenger RNA,
and in many cases only small amounts of tissue were available for
analysis. ISH is less sensitive, but allows nucleic acids to be visu-
alized in their cellular environment and was used to localize
mRNA expression in the tissues studied. However, the results of
this study must be interpreted with caution because the detection
of gene expression, as determined by the presence of mRNA, does
not necessarily imply the expression of a functional protein.
This study demonstrates for the first time, the presence of the
mRNA for GRP and its corresponding receptor and NMB in
colorectal cancer and in normal mucosa. Levels of expression are
generally higher in tumours. Using ISH we have also localized the
expression of the receptor to the epithelium rather than the stroma.
Using RT-PCR the GRP receptor appears to be reliably over
expressed in at least 70% of colorectal cancers when compared
with uninvolved mucosa. Previous radioligand binding studies
demonstrated that about 25–40% of cancers express the GRP
receptor (Radulovic et al, 1991; Preston et al, 1995), but it is unde-
tectable in normal mucosa. One possible explanation is that the
low level of expression of the GRP-R by the mucosa was not
detectable above the background in the radioligand assays but was
detectable in this study by the more sensitive RT-PCR. Only in
those tumours with overexpression of GRP-R may there be suffi-
cient binding for detection in radioligand binding assays.
Alternatively, it may be that steady-state mRNA levels do not
accurately reflect protein expression but, until validated receptor
antibodies are available, we do not have the means to investigate
this further. Our finding that GRP receptor mRNA is expressed in
colonic epithelium is at variance with a recent report (Ferris et al,
1997). The absence of expression of NMB receptor mRNA
demonstrated in this study is consistent with our studies using
radioligand binding (Preston et al, 1995) where GRP receptor but
not NMB receptor expression was demonstrated in tumour.
GRP mRNA and one of its spliced variants can be detected by
RT-PCR in approximately equal proportions in all mucosal
samples. As with the receptor, GRP ligand appears to be relatively
overexpressed in tumour when compared to matched mucosa. The
probe used for ISH studies detects mRNA both for GRP ligand
and the spliced variant. Expression of both mRNA species is
demonstrated in the mucosa rather than the stroma. In view of the
lack of expression of the NMB-R in the tumour and mucosa, the
finding of abundant NMB ligand in both was unexpected. As with
the GRP-receptor and GPR, the expression of NMB was strongest
in the tumours. Previous studies have provided evidence that GRP,
NMB and other bombesin-like peptides can bind to either the
GRP-receptor or NMB-receptor but differ in their relative affini-
ties in different species (Jensen and Coy, 1991; Wang et al, 1992;
Wang et al, 1993; Benya et al, 1995). At present we have little
knowledge of the local concentrations of NMB and GRP at any
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Table 2 RT-PCR primers
mRNA Sequence
GRP receptor Sense GGCGCTCTCGGCAGACAGATAC
Antisense TAATGAAGGTCTGGTTGGTGC
GRP ligand (Abi Olibo) Sense ATAGAAGCAAAGGAGAACAG
Antisense GAAAGATACAGAATAGTCAAA
NMB receptor (Oswel) Sense TATTTCCTCATACCACTTGC
Antisense GCTTTCCGTGTTTCCATCTGT
NMB ligand (Oswel) Sense GGGGGCGCTCGGATGTTCGG
Antisense TCAGGGAGGTGTGGGGAGCTG
BRS-3 receptor Sense CTGCGTCTGGATCGTGTCTA
Antisense TTCGGGATTCAATCTGCTTA
Figure 4 Frozen sections of colorectal cancer following in situ hybridization
with antisense (A) and sense (B) riboprobes specific for GRP receptor
A
Bone time, and therefore it is difficult to define their relative roles. It
may be that NMB has paracrine activity on the adjacent smooth
muscle (Bitar et al, 1993) providing a mechanism by which the
mucosa may influence colonic motility.
In this small series it has not been possible to demonstrate a
relationship between GRP and its receptor mRNA expression and
conventional pathological features of colorectal cancer. It was
observed, however, that more advanced tumours showed a lower
level of expression. Confirmation of these finding would require a
more accurately quantifiable method as well as a much larger
series of samples.
This study provides further evidence for the presence of
bombesin family ligands and receptors in the colon and rectum
although their role in colorectal cancer remains to be determined.
There have been several previous studies which support a role for
the bombesin-like peptides in colorectal mitogenesis. Bombesin
has been shown to stimulate rat colonic mucosal DNA synthesis
(Johnson and Guthrie, 1983) and immunoreactive bombesin/GRP
is abundant in the myenteric plexus and submucosal layer of the
human colon (Price et al, 1984) where it may stimulate the growth
of cancer cells in a paracrine manner. The murine colon cancer cell
line MC-26 exhibits a dose dependent growth response to
bombesin (Narayan et al, 1990). RC-3095, a bombesin antagonist,
inhibits the growth of HT-29 human colon cancer xenografts in
nude mice significantly reducing tumour volume, percentage
change in tumour volume and tumour weights (Radulovic et al,
1991). Colo320HSR, a colon cancer cell line expresses GRP
receptors and immunostains for GRP, suggesting an autocrine loop
as seen in SCLC (own unpublished data). There are, however,
other mechanisms by which bombesin-like peptides may stimulate
cancer cell growth. GRP is known to affect the secretion of a
number of gut peptides (Sunday et al, 1988) and may thus indi-
rectly stimulate cell growth and division.
The findings in this study, together with the above, support a
role for bombesin-like peptides in colorectal mitogenesis and
tumorigenesis. They also support the potential of bombesin antag-
onists in the treatment of advanced colorectal cancer. Further
progress in this area would benefit from the production of specific
antibodies to the GRP receptor so that receptor expression could
be correlated with prognosis in a large series of patients with
colorectal cancer and a known outcome. Funded in part by the
Wesser Medical Trust and the Wesser Cancer Trust.
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